Anbio Biotechnology
Business
Anbio Biotechnology develops and supplies in vitro diagnostic (IVD) products for infectious diseases, cancer, cardiovascular diseases, and other medical conditions. The company collaborates with third-party laboratories to develop assays using established IVD technology platforms and outsources manufacturing to suppliers while retaining revenue from sales. Products include lateral flow immunoassays (LFIA), fluorescence immunoassays (FIA), molecular assays (LAMP, RT-PCR), dry chemistry, and chemiluminescence immunoassays (ChLIA), marketed across the European Union, Asia Pacific, Africa, and the Americas through distributors and direct sales channels.
Summary from 20-F filed 2026-04-07
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | $8.65M |
| Net income | $6.40M |
| Total assets | $30.24M |
| Total liabilities | $87.8K |
| Stockholders' equity | $30.16M |
| Operating cash flow | $-6.74M |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Anbio Biotechnology's CIK number?
Anbio Biotechnology's SEC CIK number is 0001982708 (1982708). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Anbio Biotechnology's SEC filings?
All of Anbio Biotechnology's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.